The Lymph-Brain Revolution Podcast
Oct 8, 2026 · 46 min · 14 segments
What if the biggest story about **GLP-1 drugs** has very little to do with the number on your bathroom scale? Most people know **Ozempic, Wegovy and Zepbound** because of weight loss. But new…
John OssipinskyHost

It's released primarily from specialized cells in your intestine after you eat.

It participates in the regulation of blood sugar and appetite by helping stimulate insulin when glucose is elevated, reducing glucagon under appropriate conditions, slowing gastric emptying, and contributing to the feeling of satiety.

Satiety is that important signal telling your brain that you've had enough to eat.




That distinction matters because we often casually refer to all these medications as GLP-1s, even though they're not pharmacologically identical.

In the SURMOUNT-5 trial, researchers directly compared tirzepatide with semaglutide for 72 weeks in adults with obesity who did not have diabetes.

Tirzepatide produced greater reductions in body weight and waist circumference than semaglutide.

That's important clinically, but today's episode isn't about deciding which medication produces the greatest weight loss.

The question I'm more interested in is why manipulating these metabolic hormone pathways appears to affect so many different parts of the body.

To understand that, we have to leave the bathroom scale behind and follow the signal to the brain.

Your digestive system is continually sending information to your brain about what's happening inside your body, and GLP-1 is a part of that communication.

GLP-1 receptors are found in areas of the nervous system involved in appetite, energy regulation, and reward.

But the process is more complicated than saying that a drug crosses the blood-brain barrier and turns off hunger.

Scientists are still investigating exactly how different GLP-1 medications influence different regions of the human brain.

Some areas are more accessible to circulating signals, while neural pathways involving structures such as the vagus nerve can also help transmit information between the digestive system and brain.

A message doesn't have to travel directly into every neighborhood to influence what's happening throughout the city.

It can arrive at an important transportation or communication hub where that information affects activity elsewhere in the network.

That's a useful way to think of GLP-1 signaling because we're not dealing with one drug traveling everywhere in the brain and flipping one appetite switch.

We're dealing with a biological network that influences hunger, energy regulation, and something else that's becoming increasingly interesting: reward.


It's released primarily from specialized cells in your intestine after you eat.

It participates in the regulation of blood sugar and appetite by helping stimulate insulin when glucose is elevated, reducing glucagon under appropriate conditions, slowing gastric emptying, and contributing to the feeling of satiety.

Satiety is that important signal telling your brain that you've had enough to eat.




That distinction matters because we often casually refer to all these medications as GLP-1s, even though they're not pharmacologically identical.

In the SURMOUNT-5 trial, researchers directly compared tirzepatide with semaglutide for 72 weeks in adults with obesity who did not have diabetes.

Tirzepatide produced greater reductions in body weight and waist circumference than semaglutide.

That's important clinically, but today's episode isn't about deciding which medication produces the greatest weight loss.

The question I'm more interested in is why manipulating these metabolic hormone pathways appears to affect so many different parts of the body.

To understand that, we have to leave the bathroom scale behind and follow the signal to the brain.

Your digestive system is continually sending information to your brain about what's happening inside your body, and GLP-1 is a part of that communication.

GLP-1 receptors are found in areas of the nervous system involved in appetite, energy regulation, and reward.

But the process is more complicated than saying that a drug crosses the blood-brain barrier and turns off hunger.

Scientists are still investigating exactly how different GLP-1 medications influence different regions of the human brain.

Some areas are more accessible to circulating signals, while neural pathways involving structures such as the vagus nerve can also help transmit information between the digestive system and brain.

A message doesn't have to travel directly into every neighborhood to influence what's happening throughout the city.

It can arrive at an important transportation or communication hub where that information affects activity elsewhere in the network.

That's a useful way to think of GLP-1 signaling because we're not dealing with one drug traveling everywhere in the brain and flipping one appetite switch.

We're dealing with a biological network that influences hunger, energy regulation, and something else that's becoming increasingly interesting: reward.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.